NCT01128556 is a Phase 4 clinical trial of Bepreve in Histamine Responsive Allergy Patients, sponsored by North Texas Institute for Clinical Trials.

Who is sponsoring NCT01128556?

NCT01128556 is sponsored by North Texas Institute for Clinical Trials.

What drugs are being tested in NCT01128556?

Interventions in NCT01128556: Bepreve, Refresh Tears.

What condition does NCT01128556 study?

NCT01128556 studies Histamine Responsive Allergy Patients.

Is NCT01128556 still recruiting?

NCT01128556 is currently completed. Last updated 7 July 2010.

Last reviewed 2010-07-07 · How we verify

NCT01128556

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

Completed Phase 4 Last updated 7 July 2010

What this trial tests

Phase 4 trial testing Bepreve in Histamine Responsive Allergy Patients in 30 participants. Completed in 1 June 2010.

Timeline

1 April 2010

Primary endpoint
1 June 2010

1 June 2010

Quick facts

Lead sponsor	North Texas Institute for Clinical Trials
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Enrollment	30
Start date	1 April 2010
Primary completion	1 June 2010
Estimated completion	1 June 2010
Sites	1 location across United States

Drugs / interventions tested

Bepreve (BEPOTASTINE) — full drug profile →
Refresh Tears — full drug profile →

Conditions studied

Histamine Responsive Allergy Patients — all drugs for Histamine Responsive Allergy Patients →

Sponsor

North Texas Institute for Clinical Trials

Who can join

Adults 18 to 65, any sex, with Histamine Responsive Allergy Patients. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

measurement of Wheal and Flare response from histamine skin-prick testing
Time frame: 7 days

Sponsor's own description

To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01128556 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by North Texas Institute for Clinical Trials
Last refreshed: 7 July 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01128556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing